Results 41 to 50 of about 53,280 (246)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis

Rheumatology and Therapy, 2019
Introduction No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice.
George W. Reed, Robert A. Gerber, Ying Shan, Liza Takiya, Kimberly J. Dandreo, David Gruben, Joel Kremer, Gene Wallenstein   +7 more
doaj   +1 more source

Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?

Current Therapeutic Research, 2021
: Background: Concerns have been raised that the risk of severe acute respiratory syndrome coronavirus 2 infection, or more severe or critical coronavirus disease 2019 (COVID-19), may be higher in immunocompromised individuals receiving immunomodulatory
Samantha Howland, MPharm, J. Jasper Deuring, PhD, Xiaofeng Zhou, PhD, Yan Chen, MD, PhD, Licia MH Mota, MD, Ryan C. Ungaro, MD, MS   +5 more
doaj   +1 more source

Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis [PDF]

, 2013
BACKGROUND: Tofacitinib is a disease-modifying antirheumatic drug (DMARD) which was recently approved by US Food and Drug Administration (FDA). There are several randomised clinical trials (RCTs) that have investigated the efficacy and safety of ...
Chan, EWY, Chui, CSL, He, Y, Lau, WCY, Man, KC, Wong, AYS, Wong, ICK, Worsley, AJ   +7 more
core   +3 more sources

Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis [PDF]

, 2017
Objectives Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes.
Caslake, Muriel, McCarey, David, McInnes, Iain, Packard, Chris J., Porter, Duncan, Robertson, Jamie, Sattar, Naveed   +6 more
core   +1 more source

Tofacitinib is not a biologic

Annals of Gastroenterology, 2016
As the Global Medical Aff airs Gastroenterology Lead for tofacitinib at Pfi zer, I read with great interest the review by Dr Ungar and Dr Kopylov entitled “Advances in the development of new biologics in infl ammatory bowel disease (IBD)” [1]. In reading the article, I identifi ed a number of inaccuracies concerning tofacitinib, which I thought should ...
openaire   +2 more sources

Interleukin-2 shapes the cytotoxic T cell proteome and immune environment sensing programs [PDF]

, 2018
Proteomic analysis reveals how the cytokine IL-2 enables cytotoxic T cells to function and respond to their environment.
Brady, Hugh J. M., Cantrell, Doreen, Rollings, Christina, Ross, Sarah, Sinclair, Linda   +4 more
core   +2 more sources

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis

Arthritis Research & Therapy
Background Tofacitinib is an oral Janus kinase inhibitor for treatment of ankylosing spondylitis (AS). Time to improvement in core domains of AS was estimated in tofacitinib-treated patients with AS. Methods This post hoc analysis used phase 3 trial data
Victoria Navarro-Compán, Atul Deodhar, Rachid Bahiri, Andrew G. Bushmakin, Joseph C. Cappelleri, Jihane Rammaoui   +5 more
doaj   +1 more source

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry

ACR Open Rheumatology, 2021
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared 5‐year adverse event (AE) incidence rates (IRs) between patients initiating tofacitinib and those initiating new biological disease ...
Joel M. Kremer, Clifton O. Bingham III, Laura C. Cappelli, Jeffrey D. Greenberg, Ann M. Madsen, Jamie Geier, Jose L. Rivas, Alina M. Onofrei, Christine J. Barr, Dimitrios A. Pappas, Heather J. Litman, Kimberly J. Dandreo, Andrea B. Shapiro, Carol A. Connell, Arthur Kavanaugh   +14 more
doaj   +1 more source

Real-World Efficacy and Safety of Tofacitinib for Patients With Alopecia Areata: A Retrospective Multi-Center Cohort Study. [PDF]

Clin Transl Sci
ABSTRACT The approval of baricitinib and ritlecitinib for alopecia areata (AA) marks the beginning of the Janus kinase (JAK) inhibitor era in AA treatment. Tofacitinib, a first‐generation JAK1/3 inhibitor, has theoretical potential to treat AA; however, real‐world evidence, particularly on comparative outcomes across patient subgroups and patient ...
Jin Y, Cao J, Yang S, Liu Y, Tang R, Zeng Y, Huang C, Luo Y.   +7 more
europepmc   +2 more sources

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core